🌍 Psychedelics Work. Access Doesn’t.

👋 Welcome

Hey friends!

This week feels like another one of those moments where everything is moving at once.

From longevity experiments to new research on how these compounds affect perception, the conversation keeps expanding. Policy is shifting fast across multiple states. At the same time, business and biotech interest continues to grow behind the scenes.

It’s not just one lane anymore. Science, culture, and policy are all accelerating together.

Let’s get into it.

🔝 Weekly Highlights

• 🧬 Bryan Johnson calls 5-MeO-DMT the most powerful human reset he’s experienced

  Longevity entrepreneur Bryan Johnson continues to push boundaries, this time exploring 5-MeO-DMT as part of his broader health protocol. He described the experience as a kind of full-system reset, raising questions about how altered states might influence biological markers tied to aging and recovery. See Bryan’s experience
  

• 🧠 Psychedelics may impact younger people differently than older adults

  New research suggests age could play a major role in how these compounds affect mental health outcomes. Early findings indicate younger individuals may experience different psychological effects compared to older populations, opening the door to more personalized approaches in future studies. Read the research

🧬 Quick Hits

RESEARCH 🔬

• ⏳ Psychedelics may alter how we experience time

  A new study explored how these compounds disrupt working memory and attention, leading to noticeable distortions in time perception. Participants reported shifts in how long moments felt, which could help explain some of the deeper psychological effects during sessions. Explore the findings
  

• 🍄 More than one compound may drive mushroom effects

  Researchers are beginning to look beyond psilocybin alone, suggesting other naturally occurring compounds in mushrooms may contribute to the overall experience and therapeutic outcomes. Dive deeper
  

• 💰 Therapy could save thousands per patient

  A new economic model found psilocybin-assisted therapy may reduce treatment costs by around $7,000 per patient compared to standard care for treatment-resistant depression. See the analysis
  

• 🧠 VR and psychedelics may work together

  Researchers are exploring how virtual reality combined with psychedelic therapy could help restore brain function, potentially enhancing treatment outcomes through immersive environments. Learn more

POLICY 🏛️

• 🌆 King County makes psychedelics lowest enforcement priority

  Officials in the Seattle area have moved enforcement to the lowest priority level, signaling a continued shift in how local governments approach these substances. See what changed
  

• ⚖️ Mississippi expands research while restricting cannabis bills

  The governor vetoed expanded medical marijuana access while approving a measure supporting psychedelic research, highlighting the complex policy landscape across states. Read the update
  

• 🧠 Louisiana moves toward therapy pilot program

  State senators approved a bill to create a psychedelic therapy program funded by opioid settlement dollars, aimed at addressing mental health and addiction. Follow the bill
  

• 🍄 South Dakota prepares for future federal approval

  New legislation would allow synthetic psilocybin therapy if federal approval is granted, positioning the state ahead of potential regulatory shifts. See details
  

• 💸 New Mexico funds access for low-income patients

  A new initiative will support psychedelic therapy for underserved populations, focusing on expanding access rather than limiting it. Learn more
  

• ⚠️ Lobbying complaints raise concerns

  New allegations suggest potential illegal lobbying tied to psychedelic policy efforts, adding another layer to the rapidly evolving political landscape. Read the report
  

• 🌺 Hawaii advances psychedelic task force

  A House panel moved forward a bill to create a task force after it already passed the Senate, signaling continued momentum. Track progress

BUSINESS 💼

• 🧬 Atai-Beckley may sell key drug candidate

  Reports suggest the company could be exploring a sale of its flagship psychedelic treatment as industry interest continues to grow. See the report
  

• ☕ Colorado opens first microdosing café

  A new café concept in Denver is bringing microdosing into a more public-facing setting, blending wellness culture with everyday environments. Take a look
  

• 💰 Gilgamesh secures $60M after AbbVie deal

  The biotech company is expanding its pipeline with new funding, signaling continued pharmaceutical interest in the space. Read more
  

• 🧪 Clearmind files new patent in India

  The company is advancing next-generation compounds targeting mental health and addiction through new intellectual property filings. Explore details
  

🌈 Main Feature

MDMA therapy works. The real problem is who can actually afford it.

Australia became one of the first countries to allow it for PTSD in a regulated clinical setting, marking a major step forward for the field. For years, this kind of treatment existed mostly inside clinical trials. Now it’s beginning to move into the real world—and the results are holding up.

Patients with long-standing PTSD are reporting meaningful improvements, including people who had already tried multiple forms of treatment without success. That part of the story is becoming clearer: the therapy works.

But as access begins to open, another reality comes into focus alongside it.

MDMA therapy isn’t a simple intervention. It requires preparation, extended guided sessions with trained professionals, and integration afterward. The structure is intentional—and it’s part of what makes the outcomes so strong. At the same time, it makes the treatment expensive.

In Australia, costs can range from $10,000 to $25,000+ per patient, which creates a gap. Not because the therapy doesn’t exist, but because the system around it is still early.

Right now, access depends on a mix of factors: the number of trained providers, clinic capacity, and whether someone can afford the full process. Even in places where the therapy is legal, that combination limits how widely it can actually reach people.

This isn’t unusual for new forms of care. Early access is often constrained while infrastructure catches up. What’s different here is the pace. The field is moving quickly, and the demand is already there.

More countries are exploring regulated models. More providers are entering training pipelines. And more conversations are happening around cost, scalability, and potential insurance coverage. The system is being built in real time.

So both things can be true at once.

The therapy is real. And access is still uneven.

That tension will likely shape what comes next—not whether these treatments work, but how they expand without losing the structure that makes them effective.

👉 Read the full story

💡 The Movement Behind Microdosing

Legalization is moving.

Research is expanding.
Public interest keeps growing.

But none of it sustains itself.

Behind every headline, there’s a layer most people never see — the work required to actually build the systems that make access real.

Policy doesn’t organize itself.
Research doesn’t fund itself.
Education doesn’t scale on its own.

That’s where the Microdosing Collective comes in.

Over the last few years, they’ve grown into a community-backed nonprofit helping push this entire movement forward — from funding research to sitting in rooms with lawmakers shaping what comes next.

Their work spans:
• Policy advocacy at the state level
• Funding safety and therapeutic research
• Hosting events that connect researchers, donors, and decision-makers
• Creating free educational resources for the public
• Speaking and teaching around the world

It’s the kind of infrastructure that determines whether this space evolves responsibly… or gets ahead of itself.

And it’s being built almost entirely through community support.

That’s where the Giving Circle comes in.

For as little as 50¢ a day, supporters help fund the next phase of microdosing legalization — not just making it possible, but making sure it’s done right.

It’s a small commitment that compounds into something much bigger.

As a thank you, members also receive free and discounted products from partners like SuperMush, Alice Mushrooms, Open Meditation Studio, and FUNGUY.

Every level contributes.
What matters most is consistency.

Because if access expands…

The systems behind it need to be ready.

👉 Join the Giving Circle

👋 Signoff

That’s it for this week.

The science keeps moving. The policy landscape keeps shifting. And the cultural conversation around psychedelics continues expanding into places that once seemed impossible.

Have a great weekend!

✅ No one can stop you from seeing what’s delivered directly to your email. 

You’re already subscribed - congratulations!

You beat the algorithm 😉 

Thank you for joining us as we continue to navigate this ever-changing landscape.

P.S. Explore what they don’t want you to see - check us out on X (Twitter) and Instagram, and dive deeper into all things psychedelic on our website. 🌐✨